| Lung Non-Small Cell Carcinoma altered in cohorts of …ALTERED_INderived200 of 694show all (up to 200) |
|---|
| ← altered in cohorts of | ABCC5 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP11B 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC39 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DVL3 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT4-ECE2 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPHB3 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL6 444 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCF3 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRD 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN2 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCUN1D1 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF2B5 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3C 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3E 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAGEF1 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAP6D1 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MECOM 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARL 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SOX2 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNIK 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS8 443 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBBX 443 / 504 cases (88 %) · ssm · TCGA-LUSC · largest of 4 cohorts | — | — | Lung Squamous Cell Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | AP2M1 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C3orf70 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G1 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM131A 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FXR1 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GHSR 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL24 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMP3 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MB21D2 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCCC1 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCF2L2 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NLGN1 442 / 504 cases (88 %) · ssm · TCGA-LUSC · largest of 2 cohorts | — | — | Lung Squamous Cell Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA16 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THPO 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTC14 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP13 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR49 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YEATS2 442 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALG3 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A5 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B3GNT5 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN11 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC19 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECT2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EEF1AKMT4 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR3D 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNMB2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MASP1 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NAALADL2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | P3H2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR2H 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKCI 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF10 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B2 441 / 504 cases (88 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR160 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD1 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SKIL 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM212 440 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EHHADH 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV5 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FGF12 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGF2BP2 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAP3K13 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEX5L 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLAAT1 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINI1 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM41A 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP63 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZMAT3 439 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL6A 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLDN1 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DLG1 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIPH 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC15 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBL1XR1 438 / 504 cases (87 %) · ssm · TCGA-LUSC | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CD84 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2A 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLA 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JTB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB13 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS27 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UAP1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UHMK1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHO1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFX5 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf189 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf226 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDR2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP12 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAX1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF8 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL6R 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ILF2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ10 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NOS1AP 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A13 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D1B 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF7 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPATA46 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TCHH 374 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNN3 372 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NUP210L 371 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAR 370 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP8B2 370 / 573 cases (65 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 370 / 573 cases (65 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AQP10 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NPR1 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PKLR 369 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP1A4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRP 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECM1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GOLPH3L 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ITLN1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MCL1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MLLT11 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGM 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMB4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SELENBP1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF9 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS45 56 / 87 cases (64 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | VSIG8 56 / 87 cases (64 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNB2 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHTOP 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CLK2 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND4B 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 3 cohorts | — | — | Lung Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | IQGAP3 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBXIP1 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEAR1 368 / 573 cases (64 %) · ssm · TCGA-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PI4KB 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | PRUNE1 368 / 573 cases (64 %) · ssm · TCGA-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |